Last reviewed · How we verify
NCT04368546
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
trial testing Sunitinib in Renal Cell Cancer Metastatic in 6 participants. Completed in 1 March 2020.
1 February 2019
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6 |
| Start date | 1 November 2015 |
| Primary completion | 1 February 2019 |
| Estimated completion | 1 March 2020 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Sunitinib (sunitinib) — full drug profile →
Conditions studied
- Renal Cell Cancer Metastatic — all drugs for Renal Cell Cancer Metastatic →
- Hypertension — all drugs for Hypertension →
- Sodium Imbalance — all drugs for Sodium Imbalance →
Sponsor
Charite University, Berlin, Germany
Who can join
Adults 18 to 70, male only, with Renal Cell Cancer Metastatic or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment side-effect of sunitinib, hypertension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04368546
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sunitinib
Trials testing the same drug.
- NCT07218926 — A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatini · Phase 3 · recruiting
- NCT07165418 — A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcino · Phase 3 · not yet recruiting
- NCT05773274 — Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe · Phase 2 · recruiting
- NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
- NCT06032728 — Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Tre · NA · not yet recruiting
Other recruiting trials for Renal Cell Cancer Metastatic
Currently open trials in the same condition.
- NCT07197580 — Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC · Phase 3 · recruiting
- NCT07240610 — Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma · recruiting
- NCT03634540 — A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinom · Phase 2 · active not recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04368546 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 27 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04368546.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing